Hormones, nevi, and melanoma: An approach to the patient

Journal of the American Academy of Dermatology

Volumn 57, Issue 6, 2007, Pages 919-931

  Driscoll, Marcia S ^a   Grant Kels, Jane M ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ISOSULFAN BLUE; LIDOCAINE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TECHNETIUM SULFUR COLLOID TC 99M;

CANCER SURVIVAL; DIFFERENTIAL DIAGNOSIS; DRUG SAFETY; EPILUMINESCENCE MICROSCOPY; FEMALE; HISTOPATHOLOGY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MATERNAL AGE; MELANOCYTIC NEVUS; MELANOMA; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR BIOPSY;

DYSPLASTIC NEVUS SYNDROME; FEMALE; HORMONES; HUMANS; MELANOMA; NEOPLASM METASTASIS; PLACENTA DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 36049050338     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.08.045     Document Type: Review

References (94)

1. Winton G.B., and Lewis C.W. Dermatoses of pregnancy. J Am Acad Dermatol 6 (1982) 977-998
2. Parmley T., and O'Brien T.J. Skin changes during pregnancy. Clin Obstet Gynecol 33 (1990) 713-717
3. Hu W., Nelson J.E., Mohney C.A., and Willen M.D. Malignant melanoma arising in a pregnant African American woman with a congenital blue nevus. Dermatol Surg 30 (2004) 1530-1532
4. Foucar E., Bentley T.J., Laube D.W., and Rosai J. A histopathologic evaluation of nevocellular nevi in pregnancy. Arch Dermatol 121 (1985) 350-354
5. Sanchez J.L., Figueroa L.D., and Rodriguez E. Behavior of melanocytic nevi during pregnancy. Am J Dermatopathol 6 Suppl 1 (1984) 89-91
6. Ellis D.L. Pregnancy and sex steroid hormone effects on nevi of patients with the dysplastic nevus syndrome. J Am Acad Dermatol 25 (1991) 467-482
7. Pennoyer J.W., Grin C.M., Driscoll M.S., Dry S.M., Walsh S.J., Gelineau J.P., et al. Changes in size of melanocytic nevi during pregnancy. J Am Acad Dermatol 36 (1997) 378-382
8. Clark Jr. W.H., Reimer R.R., Greene M., Ainsworth A.M., and Mastrangelo M.J. Origin of familial malignant melanomas from heritable melanocytic lesions. Arch Dermatol 114 (1978) 732-738
9. Tucker M.A., Fraser M.C., Goldstein A.M., Struewing J.P., King M.A., Crawford J.T., et al. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer 94 (2002) 3192-3209
10. Halpern A.C., Guerry IV D., Elder D.E., Trock B., Synnestvedt M., and Humphreys T. Natural history of dysplastic nevi. J Am Acad Dermatol 29 (1993) 51-57
11. Banky J.P., Kelly J.W., English D.R., Yeatman J.M., and Dowling J.P. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 141 (2005) 998-1006
12. Zalaudek I., Wolf I.H., Hofmann-Wellenhof R., Leinweber B., Stefani A.D., Argenziano G., et al. Dermatoscopic follow-up of changing melanocytic skin lesion during pregnancy: from nevus to melanoma?. Melanoma Res 14 (2004) 323-325
13. Zampino M.R., Corazza M., Costantino D., Mollica G., and Virgili A. Are melanocytic nevi influenced by pregnancy? A dermatoscopic evaluation. Dermatol Surg 32 (2006) 1497-1504
14. Stolz W., Riemann A., and Cognetta A.B. ABCD rule of dermoscopy: a new practical method of early recognition of malignant melanoma. Eur J Dermatol 4 (1994) 521-527
15. Pack G.T., and Scharnagel I.M. The prognosis for malignant melanoma in the pregnant woman. Cancer 4 (1951) 324-334
16. Byrd B.F., and McGanity W.J. The effect of pregnancy on the clinical course of malignant melanoma. South Med J 47 (1954) 196-200
17. Conybeare R.C. Malignant melanoma in pregnancy: report of three cases. Obstet Gynecol 24 (1964) 451-454
18. Riberti C., Margola G., and Bertani A. Malignant melanoma: the adverse effect of pregnancy. Br J Plast Surg 34 (1981) 338-339
19. Pennington D.G. Multiple primary melanoma in pregnancy: a case report. Br J Plast Surg 36 (1983) 260-261
20. Reintgen D.S., McCarty K.S., Vollmer R., Cox E., and Seigler H.F. Malignant melanoma and pregnancy. Cancer 55 (1985) 1340-1344
21. McManamny D.S., Moss A.L.H., Pocock P.V., and Briggs J.C. Melanoma and pregnancy: a long-term follow-up. Br J Obstet Gynaecol 96 (1989) 1419-1423
22. Wong J.H., Sterns E.E., Kopald K.H., Nizze J.A., and Morton D.L. Prognostic significance of pregnancy in stage I melanoma. Arch Surg 124 (1989) 1227-1231
23. Slinguff Jr. C.L., Reintgen D.S., Vollmer R., and Seigler H.F. Malignant melanoma arising during pregnancy: a study of 100 patients. Ann Surg 211 (1990) 552-559
24. Daryanani D., Plukker J.T., De Hullu J.A., Kuiper H., Nap R.E., and Hoekstra H.J. Pregnancy and early-stage melanoma. Cancer 97 (2003) 2248-2253
25. MacKie R.M., Bufalino R., Morabito A., Sutherland C., and Cascinellil N. Lack of effect of pregnancy on outcome of melanoma. Lancet 337 (1991) 653-655
26. Driscoll M.S., Grin-Jorgensen C.M., and Grant-Kels J.M. Does pregnancy influence the prognosis of malignant melanoma?. J Am Acad Dermatol 29 (1993) 619-630
27. Lens M.B., Rosdahl I., Ahlbom A., Farahmand B.Y., Synnerstad I., Boeryd B., et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol 22 (2004) 4369-4375
28. O'Meara A.T., Cress R., Xing G., Danielsen B., and Smith L.H. Malignant melanoma in pregnancy: a population-based evaluation. Cancer 103 (2005) 1217-1226
29. Anderson J.F., Kent S., and Machin G. Maternal malignant melanoma with placental metastasis: a case report with literature review. Pediatr Pathol 9 (1989) 35-42
30. Dildy G.A., Moise K.J., Carpenter R.J., and Klima T. Maternal malignancy metastatic to the products of conception: a review. Obstet Gynecol Surv 44 (1989) 535-540
31. Baergen R.N., Johnson D., Moore T., and Benirschke K. Maternal melanoma metastatic to the placenta: a case report and review of the literature. Arch Pathol Lab Med 121 (1997) 508-511
32. Ferreira C.M.M., Maceira J.M.P., and Coelho J.M.C.O. Melanoma and pregnancy with placental metastases: report of a case. Am J Dermatopathol 20 (1998) 403-407
33. Alexander A., Harris R.M., Grossman D., Bruggers C.S., and Leachman S.A. Vulvar melanoma: diffuse melanosis and metastasis to the placenta. J Am Acad Dermatol 50 (2004) 293-298
34. Shaw J.H.F. Malignant melanoma in Auckland, New Zealand. Surg Gynecol Obstet 166 (1988) 425-430
35. George P.A., and Fortner I.G. Melanoma with pregnancy: a report of 115 cases. Cancer 13 (1960) 854-859
36. Sutherland C.M., Loutfi A., Mather F.J., Carter R.D., and Krementz E.T. Effect of pregnancy upon malignant melanoma. Surg Obstet Gynecol 157 (1983) 443-446
37. Bork K., and Brauninger W. Pregnancy following malignant melanoma: a follow-up study of 23 patients. Dtsch Med Wochenschr 35 (1985) 1323-1327
38. Hersey P., Morgan G., Stone D.E., McCarthy W.H., and Milton G.W. Previous pregnancy as a protective factor against death from melanoma. Lancet 1 (1977) 451-452
39. Elwood J.M., and Coldman A.J. Previous pregnancy and melanoma prognosis. [letter]. Lancet 2 (1978) 1000-1001
40. Rampen F.H.J., and Mulder J.H. Malignant melanoma: an androgen-dependent tumour?. Lancet 1 (1980) 562-565
41. Lederman J.S., and Sober A.J. Effect of prior pregnancy on melanoma survival. [letter]. Arch Dermatol 121 (1985) 716
42. Coulbourn D.S., Nathanson L., and Belilos E. Pregnancy and malignant melanoma. Semin Oncol 16 (1989) 377-387
43. Bork K., and Brauninger W. Prior pregnancy and melanoma survival. [letter]. Arch Dermatol 122 (1986) 1097
44. Bork K., and Brauninger W. Endocrine influences on malignant melanoma. Dtsch Med Wochenschr 106 (1981) 1329-1333
45. Travers R.L., Sober A.J., Berwick M., Mihm Jr. M.C., Barnhill R.L., and Duncan L.M. Increased thickness of pregnancy-associated melanoma. Br J Dermatol 132 (1995) 876-883
46. Shapiro R.L. Surgical approaches to malignant melanoma: practical guidelines. Dermatol Clin 20 (2002) 681-699
47. Sweeney S.M., and Maloney M.E. Pregnancy and dermatologic surgery. Dermatol Clin 24 (2006) 205-214
48. Lawrence C. Drug management in skin surgery. Drugs 52 (1996) 805-817
49. Gormley D.E. Cutaneous surgery and the pregnant patient. J Am Acad Dermatol 23 (1990) 269-279
50. Rosenberg P.H., Veering B.T., and Urmey W.F. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med 29 (2004) 564-567
51. Mondi M.M., Cuena R.E., Ollila D.W., Stewart JH I.V., and Levine E.A. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol (2006) Oct 25 [E-pub ahead of print]
52. Squatrito R.C., and Harlow R.C. Melanoma complicating pregnancy. Obstet Gynenecol Clin North Am 25 (1998) 407-416
53. Keleher A., Wendt R., Delpassand E., Stachowiak A.M., and Kuerer H.M. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99 m sulfur colloid. Breast J 10 (2004) 492-495
54. Schwartz J.L., Mozurkewich E.L., and Johnson T.M. Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant. Cancer 97 (2003) 2130-2133
55. Amersi F., and Hansen N.M. The benefits and limitations of sentinel lymph node biopsy. Curr Treat Options Oncol 7 (2006) 141-151
56. Lloyd M.S., Topping A., Allan R., and Powell B. Contraindications to sentinel lymph node biopsy in cutaneous malignant melanoma. Br J Plast Surg 57 (2004) 725-727
57. Campbell F.A., and Campbell C. Magnetic resonance imaging for Stage IV melanoma during pregnancy. Arch Dermatol 142 (2006) 393
58. Beyeler M., Hafner J., Beinder E., Fauchere J.C., Stoeckli S.J., Fehr M., et al. Special considerations for Stage IV melanoma during pregnancy. Arch Dermatol 141 (2005) 1077-1078
59. Beral V., Ramcharan S., and Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 36 (1977) 804-809
60. Adam S.A., Sheaves S.A., Wright N.H., Mosser G., Harris R.W., and Vessey M.P. A case-control study of the possible association between oral contraceptives and malignant melanoma. Br J Cancer 44 (1981) 45-50
61. Holly E.A., Weiss N.S., and Liff J.M. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst 70 (1983) 827-831
62. Lế M.G., Cabanes P.A., Desvignes V., Chanteau M.F., Mlika N., and Avril M.F. Oral contraceptive use and the risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control 3 (1992) 199-205
63. Palmer J.R., Rosenberg L., Strom B.L., Harlap S., Zauber A.G., Warshauer M.E., et al. Oral contraceptive use and the risk of cutaneous malignant melanoma. Cancer Causes Control 3 (1992) 547-554
64. Beral V., Evans S., Shaw H., and Milton G. Oral contraceptive use and malignant melanoma in Australia. Br J Cancer 50 (1984) 681-685
65. Hannaford P.C., Villard-Mackintosh L., Vessey M.P., and Kay C.R. Oral contraceptives and malignant melanoma. Br J Cancer 63 (1991) 430-433
66. Zanetti R., Franceschi S., Rosso S., Bidoli E., and Colonna S. Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int J Epidemiol 19 (1990) 522-526
67. Osterlind A., Tucker M.A., Stone B.J., and Jensen O.M. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 42 (1988) 821-824
68. Gallagher R.P., Elwood J.M., Hill G.B., Coldman A.J., Threlfall W.J., and Spinelli J.J. Reproductive factors, oral contraceptives, and risk of malignant melanoma: Western Canada melanoma study. Br J Cancer 52 (1985) 901-907
69. Green A., and Bain C. Hormonal factors and melanoma in women. Med J Aust 142 (1985) 446-448
70. Helmrich S.P., Rosenberg L., Kaufman D.W., Miller D.R., Schottenfeld D., Stolley P.D., et al. Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. J Natl Cancer Inst 72 (1984) 617-620
71. Holman C.D.J., Armstrong B.K., and Heenan P.J. Cutaneous malignant melanoma in females: exogenous sex hormones and reproductive factors. Br J Cancer 50 (1984) 673-678
72. Bain C., Hennekens C.H., Speizer F.E., Rosner B., Willett W., and Belanger C. Oral contraceptive use and malignant melanoma. J Natl Cancer Inst 68 (1982) 537-539
73. Holly E.A., Cress R.D., and Ahn D.K. Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am J Epidemiol 141 (1995) 943-950
74. Westerdahl J., Olsson H., Masback A., Ingvar C., and Jonsson N. Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Br J Cancer 73 (1996) 1126-1131
75. Smith M.A., Fine J.A., Barnhill R.L., and Berwick M. Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol 27 (1998) 751-757
76. Naldi L., Altieri A., Imberti G.L., Giordano L., Gallus S., and La Vecchia C. Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case-control study from Italy. Ann Epidemiol 15 (2005) 545-550
77. Feskanich D., Hunter D.J., Willett W.C., Spiegelman D., Stampfer M.J., Speizer F.E., et al. Oral contraceptive use and the risk of melanoma in premenopausal women. Br J Cancer 81 (1999) 918-923
78. Karagas M.R., Stukel T.A., Dykes J., Milionico J., Greene M.A., Carey M., et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 86 (2002) 1085-1092
79. Gefeller O., Hassan K., and Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol 138 (1998) 122-124
80. Leslie K.K., and Espey E. Oral contraceptives and skin cancer: is there a link?. Am J Clin Dermatol 6 (2006) 349-355
81. Persson I., Yuen J., Berkvist L., and Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 67 (1996) 327-332
82. Holly E.A., Cress R.D., and Ahn D.K. Cutaneous melanoma in women: ovulatory life, menopause and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev 3 (1994) 661-668
83. Sober A.J., Lew R.A., Koh H.K., and Barnhill R.L. Epidemiology of cutaneous melanoma: an update. Dermatol Clin 9 (1991) 617-629
84. Neifield J.P., and Lippman M.C. Steroid hormone receptors and melanoma. J Invest Dermatol 74 (1980) 379-381
85. Grill H.J., Benes P., Manz B., Schramm P., Morsches B., Korting G.W., et al. Steroid hormone receptor analysis in human melanoma and non-malignant human skin. Br J Dermatol 107 Suppl 23 (1982) 64-65
86. Lopez R.E., Bhakoo H., Paolini N.S., Rosen F., Holyoke E.D., and Goldrosen M.H. Effect of estrogen on the growth of B-16 melanoma. Surg Forum 29 (1978) 153-154
87. Cohen C., DeRose P.B., Campbell W.G., Schlosnagle D.C., and Sgoutas D. Estrogen receptor status in malignant melanoma. Am J Dermatopathol 12 (1990) 562-564
88. Flowers J.L., Seigler H.F., KS Sr. M., Konrath J., and McCarty Jr. K.S. Absence of estrogen receptors in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. Arch Dermatol 123 (1987) 764-765
89. Lecavalier M.A., From L., and Gaid N. Absence of estrogen receptors in dysplastic nevi and malignant melanoma. J Am Acad Dermatol 23 (1990) 242-246
90. Duncan L.M., Travers R.L., Koerner F.C., Mihm Jr. M.C., and Sober A.J. Estrogen and progesterone receptor analysis in pregnancy-associated melanoma: absence of immunohistochemically detectable hormone receptors. Hum Pathol 25 (1994) 36-41
91. Duffy M.J. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci 43 (2006) 325-347
92. Schmidt A., Nanney L.B., Boyd A.S., King L.E., and Ellis D.L. Oestrogen receptor-β expression in melanocytic lesions. Exp Dermatol 15 (2006) 971-980
93. Lacal P.M., Failla C.M., Pagani E., Odorisio T., Schietroma C., Falcinelli S., et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115 (2000) 1000-1007
94. Graeven U., Rodeck U., Karpinski S., Jost M., Andre N., and Schmiegel W. Expression patterns of placenta growth factor in human melanocytic cell lines. J Invest Dermatol 114 (2000) 118-123